Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Moderna reported 2025 revenue of $1.9 billion (toward the high end of prior guidance) and secured approval and fall-market availability of its second COVID vaccine, mNEXSPIKE. The company achieved in excess of $1.0 billion in targeted cost reductions and cited $2.0 billion of total cost outs in 2025, exiting with about $8.1 billion in cash, positioning it favorably heading into 2026.

Analysis

The cost-out execution materially changes the firm's capital allocation trade-offs: management now has the choice to deploy free cash into high-return R&D bets, tuck M&A to shore up pipeline breadth, or buy back stock. That optionality crystallizes over the next 6–18 months and magnifies the value of any successful late-stage readouts because incremental incremental EBIT flows much more directly to FCF and equity value given the leaner cost base.

On competitive dynamics, lower internal cost structure shifts the battleground from margin capture to volume and contracting power. Expect procurement purchasers (governments, large health systems) to exert greater price discipline; the players that control LNP supply chains and fill/finish capacity will see outsized volatility — they can either extract higher per-unit economics or suffer from lumpy demand if primary customers internalize more manufacturing.

Key tail risks are demand deflation for repeat boosters and a regulatory or pricing regime that accelerates commoditization of COVID/adaptive mRNA products. Near-term catalysts to watch are upcoming guidance updates and any capacity/partnering announcements in the next 3–9 months; a positive sequencing of pipeline readouts plus commercial capacity deals would be a high-conviction re-rating trigger, while dampened public procurement or an adverse regulatory pivot could reverse sentiment quickly over a 1–3 quarter horizon.

Key Decisions for Investors

• Long equity + hedge (MRNA): Buy MRNA shares now and finance downside protection with a 9–12 month collar (sell a 40–50% OTM call, buy a 25–30% OTM put). R/R: asymmetric upside if next 3–9 month pipeline/capacity catalysts print; capped upside from call sale but limits drawdown to put strike — appropriate if you want exposure while locking in the operational leverage from cost cuts.
• Pair trade (long MRNA / short BNTX): Initiate a 6–12 month pair to capture differential operational leverage and balance-sheet optionality. R/R: reduces beta to sector moves; risk if a broad sector re-acceleration lifts both names simultaneously — size the short to be 50–70% of the long to retain net long upside.
• Event-driven options (MRNA): Buy 6–9 month call spread (long ATM call, short 60% OTM call) ahead of expected guidance/capacity announcements. R/R: low-cost way to capture a re-rate if management signals M&A or larger buybacks; downside limited to premium paid.
• Short selective CMOs (CTLT): Small, tactical short over the next 3–6 months in contract manufacturers that saw pandemic-era capacity tailwinds but face potential demand slip and pricing pressure. R/R: high carry/short-duration trade — biggest risk is M&A/contract wins that re-accelerate volumes; keep position size limited and monitor tender announcements weekly.